XML 59 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions and Other Transactions (Tables)
 12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed The allocation of the purchase price to the assets acquired and liabilities assumed for Oyster Point is as follows:
(In millions)
Preliminary Purchase Price Allocation as of January 3, 2023 (a)
Measurement Period Adjustments (b)
Purchase Price Allocation as of December 31, 2023 (as adjusted)
Current assets (excluding inventories and net of cash acquired)$26.9 $— $26.9 
Inventories37.8 — 37.8 
Property, plant and equipment1.4 — 1.4 
Identified intangible assets334.0 — 334.0 
Goodwill5.9 0.8 6.7 
Deferred income tax benefit17.7 (0.8)16.9 
Other assets 7.7 — 7.7 
Total assets acquired$431.4 $— $431.4 
Current liabilities37.0 — 37.0 
Other noncurrent liabilities1.7 — 1.7 
Net assets acquired (net of $34.7 of cash acquired)$392.7 $— $392.7 
__________
(a) As previously reported in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2023.
(b) The measurement period adjustments were recorded in the fourth quarter of 2023 and are related to income taxes.
The allocation of the purchase price to the assets acquired and liabilities assumed for Famy Life Sciences is as follows:
(In millions)
Preliminary Purchase Price Allocation as of January 3, 2023 (a)
Measurement Period Adjustments (b)
Purchase Price Allocation as of December 31, 2023 (as adjusted)
IPR&D$290.0 $— $290.0 
Goodwill89.3 (0.1)89.2 
Total assets acquired$379.3 $(0.1)$379.2 
Current liabilities2.2 — 2.2 
Deferred tax liabilities52.1 (0.1)52.0 
Net assets acquired (net of $0.2 of cash acquired)$325.0 $— $325.0 
__________
(a) As previously reported in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2023.
(b) The measurement period adjustment was recorded in the fourth quarter of 2023 and is related to income taxes.
Business Acquisition, Pro Forma Information
The following table presents supplemental unaudited pro forma information for the acquisition, as if it had occurred on January 1, 2022. The unaudited pro forma results reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased amortization expense based on the fair value of assets acquired, the impact of transaction costs and the related income tax effects. The unaudited pro forma results do not include any anticipated synergies which may be achievable, or have been achieved, subsequent to the closing of the acquisition. Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred had the acquisitions been completed on the stated date above, nor are they indicative of the future operating results of Viatris and its subsidiaries.
Year Ended
(Unaudited, in millions, except per share amounts)December 31, 2023December 31, 2022
Total revenues$15,426.9 $16,283.4 
Net earnings$93.8 $1,905.7 
Earnings per share:
Basic$0.08 $1.57 
Diluted$0.08 $1.57 
Weighted average shares outstanding:
Basic1,200.3 1,212.1 
Diluted1,206.9 1,217.4